Calithera Biosciences (CALA) Cut to Strong Sell at BidaskClub

BidaskClub lowered shares of Calithera Biosciences (NASDAQ:CALA) from a sell rating to a strong sell rating in a report released on Thursday.

CALA has been the topic of a number of other research reports. ValuEngine downgraded Calithera Biosciences from a hold rating to a sell rating in a research report on Friday, December 1st. Zacks Investment Research raised Calithera Biosciences from a hold rating to a buy rating and set a $19.00 price objective on the stock in a research report on Monday, November 6th. Finally, William Blair started coverage on Calithera Biosciences in a research report on Thursday, October 5th. They set an outperform rating on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Calithera Biosciences presently has an average rating of Hold and a consensus target price of $15.17.

Shares of Calithera Biosciences (CALA) opened at $8.40 on Thursday. Calithera Biosciences has a 12-month low of $4.10 and a 12-month high of $20.05. The firm has a market capitalization of $298.01, a PE ratio of -8.48 and a beta of 2.88.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $6.02 million. equities analysts predict that Calithera Biosciences will post -0.77 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC raised its stake in Calithera Biosciences by 1,279.5% in the fourth quarter. Acadian Asset Management LLC now owns 21,686 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 20,114 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Calithera Biosciences by 56.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 112,235 shares of the biotechnology company’s stock valued at $938,000 after buying an additional 40,635 shares during the last quarter. Franklin Street Advisors Inc. NC raised its stake in Calithera Biosciences by 56.2% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 55,580 shares of the biotechnology company’s stock valued at $464,000 after buying an additional 20,000 shares during the last quarter. California Public Employees Retirement System raised its stake in Calithera Biosciences by 210.1% in the third quarter. California Public Employees Retirement System now owns 43,719 shares of the biotechnology company’s stock valued at $689,000 after buying an additional 29,619 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Calithera Biosciences by 25.8% in the third quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 6,910 shares during the last quarter. Institutional investors own 72.19% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Calithera Biosciences (CALA) Cut to Strong Sell at BidaskClub” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://weekherald.com/2018/01/22/calithera-biosciences-cala-cut-to-strong-sell-at-bidaskclub.html.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply